Sugi Predict

Sugi Predict / Compounds / SCHEMBL1875520

SCHEMBL1875520

SCHEMBL1875520

C[C@@](N)(CC(=O)O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ HIF1A Q16665 2/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ ADRA1A P35348 2/20 0.50
▸ HMGCR P04035 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ TBXA2R P21731 1/20 0.50
▸ GGT1 P19440 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 4/20 0.43
▸ ARG1 P05089 1/20 0.43
▸ ARG2 P78540 1/20 0.43
▸ TDP1 Q9NUW8 2/20 0.42
▸ FFAR1 O14842 1/20 0.42
▸ CPT2 P23786 1/20 0.42
▸ BLM P54132 2/20 0.42
▸ MEN1 O00255 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162455 1.00 TSHR (0.55) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL1660876 1.00 TSHR (0.55) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Hydrochloric Acid SCHEMBL28641269 0.97 CYP2C19 (0.52) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL2721718 0.85 CYP2C19 (0.41) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Water SCHEMBL18669981 0.82 TSHR (0.39) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Phenol SCHEMBL28180129 0.82 BLM (0.56) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL161723 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL161722 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL573396 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL1986433 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370496-A1 INHIBITORS OF AMYLOID BETA OLIGOMERIZATION AND THERAPEUTIC USES THEREOF Northwestern University (US) 2024-05-22 — — EP claimed
WO-2023288284-A1 INHIBITORS OF AMYLOID BETA OLIGOMERIZATION AND THERAPEUTIC USES THEREOF NORTHWESTERN UNIVERSITY (US) 2023-01-19 — — WO claimed
WO-2021146371-A1 METHOD OF INDUCING ANALGESIA USING A HALOGENATED ALCOHOL EXPANESTHETICS, INC. (US) 2021-07-22 — — WO claimed
WO-2021138390-A1 MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-07-08 — — WO claimed
US-20250361273-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC 2025-11-27 — — US disclosed
WO-2025245483-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) 2025-11-27 — — WO disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 — — CN disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 — — CN disclosed
CN-114375333-B Compositions comprising a propeptide of lysyl oxidase and uses thereof 耶达研究及发展有限公司 2025-02-21 — — CN disclosed
EP-4504732-A2 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF University of Connecticut (US) 2025-02-12 — — EP disclosed
CN-119367342-A CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation 奥迈科斯治疗公司 2025-01-28 — — CN disclosed
CN-119072472-A FAP inhibitors 上海先通生物科技有限公司 2024-12-03 — — CN disclosed
US-7060818-B2 Synthesis of macrocyclic tetraamido compounds and new metal insertion process CARNEGIE MELLON UNIVERSITY (US) 2006-06-13 — — US disclosed
EP-0914206-B1 LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS UNIV CARNEGIE MELLON (US) 2002-12-11 — — EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
WO-1999064156-A1 LONG-LIVED HOMOGENOUS AMIDE CONTAINING MACROCYCLIC COMPOUNDS CARNEGIE MELLON UNIVERSITY (US) 1999-12-16 — — WO disclosed
EP-0914206-A1 LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS CARNEGIE-MELLON UNIVERSITY (US) 1999-05-12 — — EP disclosed
WO-1998003263-A1 LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS CARNEGIE MELLON UNIVERSITY (US) 1998-01-29 — — WO disclosed
US-5545625-A Preventing conversion of citrulline to argininosuccinate to limit pathological nitric oxide overproduction THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) 1996-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361273-A1 METHODS AND COMPOSITIONS MC4R, GPR119, MC2R TSHR 120/4885CYP2C19 3910/4885HIF1A 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.